Objective To investigate the value of long non-coding RNA (lncRNA) TMEVPG1 in the prognosis evaluation of patients with primary immune thrombocytopenia (ITP).
Methods A total of 126 ITP patients were selected as the study group. According to the prognosis of ITP patients, they were divided into poor prognosis group (n=31) and good prognosis group (n=95), and 125 healthy subjects who underwent physical examination during the same period were selected as control group. The relative expression level of lncRNA TMEVPG1 was determined by quantitative real-time polymerase chain reaction (qRT-PCR); correlations of lncRNA TMEVPG1 with platelet count, interferon-γ (IFN-γ), interleukin (IL)-2, IL-4 and IL-10 in ITP patients were explored by Pearson correlation; the factors influencing the prognosis of ITP patients were analyzed by COX regression.
Results Compared with the control group, lncRNA TMEVPG1 level in the study group was significantly decreased (P < 0.05); lncRNA TMEVPG1 level in the poor prognosis group was significantly lower than that in the good prognosis group (P < 0.05). LncRNA TMEVPG1 was positively correlated with platelet count, IL-4 and IL-10, and negatively correlated with IFN-γ and IL-2 (P < 0.05). Lower lncRNA TMEVPG1 was an independent risk factor for poor prognosis in ITP patients (P < 0.05).
Conclusion The decreased level of LncRNA TMEVPG1 is associated with poor prognosis in ITP patients, which can be used as an auxiliary indicator to evaluate the prognosis of ITP patients.
DownLoad: